Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rezolute, Inc. (RZLT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1200-0.0700 (-2.19%)
At close: 04:00PM EDT
Advertisement

Rezolute, Inc.

201 Redwood Shores Parkway
Suite 315
Redwood City, CA 94065
United States
650 206 4507
https://www.rezolutebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees26

Key Executives

NameTitlePayExercisedYear Born
Mr. Nevan Charles Elam J.D.Founder, CEO & Director1.01MN/A1967
Dr. Brian Kenneth Roberts M.D.Chief Medical Officer744.74kN/A1975
Mr. Chris MilksVP & Head of Fin.N/AN/AN/A
Mr. Michael R. DeperroSr. VP & Head of Technical OperationsN/AN/AN/A
Dr. Davelyn Eaves Hood M.B.A., M.D.Director and Head of Scientific & Patient AffairsN/AN/AN/A
Mr. Michael CovarrubiasVP & Head of CMCN/AN/AN/A
Dr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical Devel.N/AN/AN/A
Ms. Robyn SweinhartVP & Head of QualityN/AN/AN/A
Ms. Erin O'BoyleVP & Head of Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Corporate Governance

Rezolute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement